#her2
LightNews LightNews
emilychudy.bsky.social
my little sister worked on this cancer trial!! everybody say well done Liv ✨
NHS approves new treatment for aggressive cancer that could triple life expectancy
Also known as Ziihera, the antibody treatment targets a protein called HER2, which stimulates tumour growth. It works by activating the immune system to eliminate cancer cells and reduces HER2 levels
www.independent.co.uk
April 21, 2026 at 8:41 AM
ashwinvarma97.bsky.social
Ah but HER2+ continued to undergo changes. Most recently, an antibody-drug conjugate has transformed outcomes in r/r HER2+ cancer:
April 5, 2026 at 2:44 AM
ashwinvarma97.bsky.social
The one I don't have a good graph for is Breast Cancer, but that ALSO underwent huge transformations. First was HER2+ cancer, which previously had very poor prognosis. This was transformed in the early-2000s with the approval of Herceptin, the first targeted HER2 therapy:
April 5, 2026 at 2:42 AM
latashavines.bsky.social
Hi, I’m LaTasha D. Vines—Nurse Practitioner, speaker, and author of Victim to Victor: My HER2+ Breast Cancer Story. I help others heal with faith, truth, and resilience. 💗

📘 Book: www.amazon.com/dp/B0F2Z5MFL7
#VictorMethod #CancerBuddies
Victim to Victor: HER2+ My Breast Cancer Story
Victim to Victor: HER2+ My Breast Cancer Story [Vines, LaTasha] on Amazon.com. *FREE* shipping on qualifying offers. Victim to Victor: HER2+ My Breast Cancer Story
www.amazon.com
September 2, 2025 at 8:11 PM
tmprowell.bsky.social
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)

Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models

#DrugDevelopment #OncoSky

www.cell.com/cell-reports...
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC internalization. The additi...
www.cell.com
November 12, 2024 at 12:33 PM
ralfwittenbrink.bsky.social
Virusinfektionen der Atemwege wie SARS-CoV-2 und Influenza wecken metastasierende Brustkrebszellen in der Lunge

Brustkrebs ist weltweit die zweithäufigste Krebsart. Die meisten Todesfälle sind auf Metastasen zurückzuführen, oft nach langen Phasen klinischer Ruhe. Diese Studie …
Abb. 5: Eine SARS-CoV-2-Infektion erhöht das Fortschreiten von Krebs, die Metastasierung in der Lunge und die Sterblichkeit. a , Quantifizierung von HER2 + -Zellen über drei Lungenschnitte in C57BL6/J MMTV-Her2-Mauslungen an 28 dpi mit MA10 SARS-CoV-2 ( n  = 6) oder PBS-Kontrolle ( n  = 7). b , c , Quantifizierung von HER2 + -Zellen und Prozentsatz von Ki67 + HER2 + -Zellen an 3 dpi und 9 dpi mit MA10 in den Lungen von FVB MMTV-Her2-Mäusen ( n  = 3 PBS an 3 dpi und n  = 4 an 9 dpi) ( b ) und Vergleich von MMTV-Her2-Mäusen ohne (WT) oder mit Il6- Knockout ( n  = 4 pro Gruppe) ( c ). Die Signifikanz wurde durch zweiseitigen Student- t -Test bestimmt ( a , c ). Für b haben wir ein negatives Binomialmodell für HER2 + -Zellen pro Feld angewendet und dabei 9 dpi und PBS-Kontrolle verglichen (um die potenzielle Überdispersion zu berücksichtigen); für HER2 + Ki67 + -Zellen pro Feld haben wir mithilfe eines negativen Binomialmodells ermittelt, ob die Zellen pro Feld in infizierten Gruppen …
July 30, 2025 at 10:46 PM
swilua.bsky.social
Regence Blue Cross of Utah is denying chemotherapy to my friend, Raven Haymond. She is scheduled to receive Perjecta, which is the standard of care for HER2+ targeted cancers next week

You can call the ethics hotline: (888) 384-3577

email: eco@cambiahealth.com

We are also seeking media contacts
December 6, 2024 at 6:33 PM
drsgraff.bsky.social
T-DXd approved today after progression on CDK4/6 inhibitor for HR+ HER2-low and HER2-ultralow metastatic breast cancer based on results of DESTINY-Breast06. #bcsm #oncsky
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
www.astrazeneca.com
January 28, 2025 at 12:50 AM
ptarantinomd.bsky.social
The biparatopic anti-HER2 mAb zanidatamab is now approved for treating HER2+ biliary tract cancer. Zanidatamab simultaneously binds to the trastuzumab- and pertuzumab binding domain of HER2. Phase 3 trial ongoing in pretreated HER2+ MBC, led by Sara Tolaney. www.fda.gov/drugs/resour...
November 23, 2024 at 1:27 AM
ashwinvarma97.bsky.social
Let me illustrate with one example from above. HER2. Who discovered that HER2 was a protein that drove breast cancer growth? It was a researcher at UCLA named Dennis Slamon (laskerfoundation.org/winners/herc...)
Herceptin—a targeted antibody therapy for breast cancer - Lasker Foundation
H. Michael Shepard, Dennis J. Slamon, Axel Ullrich
laskerfoundation.org
April 5, 2026 at 3:03 AM
ralfwittenbrink.bsky.social
dieses Phänomen möglicherweise verursacht. Unsere Studien unterstreichen die Bedeutung der Entwicklung von Interventionen zur Minimierung des Risikos eines Erwachens der DCC in der Lunge und einer Metastasierung bei Millionen von Krebsüberlebenden, die an einer Virusinfektion der
Abb. 3: IL-6 trägt zum Erwachen ruhender DCCs und zur Proliferation bei. a – c , Lungenschnitte von MMTV-Her2- oder IL-6-KO:MMTV-Her2-Mäusen wurden an Tag 9 und 28 mit IAV (oder PBS) auf HER2 (grün) und DAPI (blau) gefärbt ( a ) und an Tag 9 ( b ) und 28 ( c ) quantifiziert. Maßstab: 50 μm. d , Quantifizierung des Prozentsatzes von HER2 + Ki67 + -Zellen in MMTV-Her2 und IL-6-Knockout:MMTV-Her2 an Tag 9 ( n  = 4 pro Gruppe). NS, nicht signifikant. e , f , Quantifizierung des Prozentsatzes von Vimentin + HER2 + ( e ) und EpCAM + HER2 + ( f ) Zellen in MMTV-Her2 und IL-6 knockout:MMTV-Her2 Mäusen an Tag 9 (Vimentin) und Tag 3 (EpCAM) ( n  = 3 für PBS, n  = 4 IAV). Die Signifikanz wurde durch eine einfaktorielle ANOVA bestimmt. g , Mittlere Mammosphärenfläche pro Vertiefung für HER2 + Organoide nach der Behandlung mit 10 ng ml −1 IL-6 ( n  = 5 pro Gruppe) ( g ); die Signifikanz wurde durch den Mann-Whitney-Test berechnet. Alle Box-and-Whisker-Diagramme werden als Maximalwert …
July 30, 2025 at 10:58 PM
voteinthemidterms.bsky.social
www.healthandme.com/health-welln...
Honey Bee Venom Can Kill Breast Cancer Cells
Australian researchers found that honeybee venom, particularly its compound melittin, can rapidly kill aggressive breast cancer cells like triple-negative and HER2-positive types while sparing healthy...
www.healthandme.com
May 31, 2026 at 11:56 AM
enirenberg.bsky.social
Occasionally, people make these autoantibodies against a target that is therapeutically useful. For example, some people naturally make an antibody against the protein HER2, which is highly expressed on some breast cancers. People with these antibodies have better outcomes than those who don't...
Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer - Breast Cancer Research and Treatment
Anti-HER2-autoantibodies (HER2-AAbs) are found in breast cancer patients as well as healthy individuals. However, the clinical relevance of the antibodies is unknown. We established an enzyme-linked i...
link.springer.com
January 12, 2025 at 3:41 AM
ralfwittenbrink.bsky.social
zeigt, dass Infektionen mit Influenza und SARS-CoV-2 zum Verlust des Pro-Dormanz-Phänotyps bei Brust-DCCs (DCC: disseminierte Krebszellen) in der Lunge führen, was innerhalb weniger Tage nach der Infektion zu einer DCC-Proliferation und innerhalb von zwei Wochen zu einer massiven
a , Quantifizierung von HER2 + -Zellen über drei Lungenschnitte in C57BL6/J MMTV-Her2-Mauslungen an 28 dpi mit MA10 SARS-CoV-2 ( n  = 6) oder PBS-Kontrolle ( n  = 7). b , c , Quantifizierung von HER2 + -Zellen und Prozentsatz von Ki67 + HER2 + -Zellen an 3 dpi und 9 dpi mit MA10 in den Lungen von FVB MMTV-Her2-Mäusen ( n  = 3 PBS an 3 dpi und n  = 4 an 9 dpi) ( b ) und Vergleich von MMTV-Her2-Mäusen ohne (WT) oder mit Il6- Knockout ( n  = 4 pro Gruppe) ( c ). Die Signifikanz wurde durch zweiseitigen Student- t -Test bestimmt ( a , c ). Für b haben wir ein negatives Binomialmodell für HER2 + -Zellen pro Feld angewendet und dabei 9 dpi und PBS-Kontrolle verglichen (um die potenzielle Überdispersion zu berücksichtigen); für HER2 + Ki67 + -Zellen pro Feld haben wir mithilfe eines negativen Binomialmodells ermittelt, ob die Zellen pro Feld in infizierten Gruppen signifikant höher als 0 waren (alle PBS-Proben waren 0). Alle Replikate sind biologisch….
July 30, 2025 at 10:48 PM
adamfeuerstein.bsky.social
Daiichi Sankyo AstraZeneca — Enhertu expanded FDA approval covering “ultra low” HER2 expression

www.astrazeneca.com/media-centre...
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
www.astrazeneca.com
January 27, 2025 at 11:25 PM
theguardian.com
Women in England with incurable breast cancer to get life-extending drug on NHS
Women in England with incurable breast cancer to get life-extending drug on NHS
Thousands with HER2-low advanced breast cancer will have access to Enhertu after ministers strike deal on price Thousands of women in England with incurable breast cancer will get access to a life-extending drug on the NHS after negotiations over its cost proved successful. About 1,000 women a year with HER2-low advanced breast cancer will be able to obtain Enhertu from Thursday after ministers and the drug’s makers struck a deal on its price. Continue reading...
www.theguardian.com
September 17, 2026 at 5:17 AM
onclive.bsky.social
WATCH 📺: In this episode of #OncLiveOnAir 🎙️, Narjust Florez, MD, of @danafarber.bsky.social, and Jonathan Wesley Riess, MD, MS, of @ucdavis.bsky.social, discuss HER2 overexpression vs HER2 mutations in NSCLC. #lcsm #oncology

Watch or listen ➡️: www.onclive.com/view/recent-...
Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC | OncLive
Drs Florez and Riess discuss the distinction between HER2 overexpression and HER2 mutations in non–small cell lung cancer.
www.onclive.com
September 25, 2026 at 12:03 AM
mauriziocallari.bsky.social
📢 Our work just published in
@naturecomms.bsky.social @natureportfolio.nature.com!
What is driving #response to #targeted #treatments in HER2+ER+ #breastcancer? How is the tumour ecosystem affected by treatment? Find the answers in our paper 👉 rdcu.be/ecbVR
Key points below 👇
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Nature Communications - NA-PHER2 was a neoadjuvant trial of HER2-targeted trastuzumab and pertuzumab plus the CDK4/6 inhibitor palbociclib with or without endocrine therapy in HER2-positive,...
rdcu.be
March 5, 2025 at 2:55 PM
oncodaily.bsky.social
SPCC: Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond

oncodaily.com/blog/227603

#BiomarkerTesting #Cancer #CancerResearch #CancerTherapy #CancerTreatmentAdvancements #ClinicalCharacteristics #HR+/HER2-MBC #MetastaticBreastCancer #OncoDaily #Health #Medicine
SPCC: Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond - OncoDaily
SPCC: Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond / biomarker testing, cancer, Cancer research, cancer therapy, cancer treatment
oncodaily.com
January 21, 2025 at 1:41 PM
pathologist.bsky.social
The human epidermal growth factor receptor 2 (HER2), one of the most common biomarkers assessed by scoring of IHC-stained tissue: Overexpressed in 15-25% of breast carcinomas (likely to respond to HER2 targeted therapy) #biomarkers #oncology #Her2 #breastcancer #pathology #surgicalpathology #pathsky
Score 0, 1+, 2+, 3 by IHC of a breast carcinoma
November 22, 2024 at 9:38 PM
nowwhat2024.bsky.social
This is wonderful news! As a er/pr- her2+ survivor, I spent many a day in the chemo chair next to my triple neg counterparts. This is such a great advancement!
November 16, 2024 at 3:19 PM
oncodaily.bsky.social
FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

oncodaily.com/insight/234405

#BreastCancer #Cancer #FDA #CancerCare #OncoDaily #Oncology #TheDESTINY-04Trial #TrastuzumabDeruxtecan #Medicine #Health
FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment - OncoDaily
FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment / Aditya Bardia, Breast Cancer, cancer, Carlos H. Barrios, FDA, Gargi Patel, Giuseppe
oncodaily.com
January 29, 2025 at 10:42 PM
oldladywithcat.bsky.social
Can you please do HER2 positive metastatic breast cancer? Hurry.
lukeepplin.bsky.social Luke Epplin @lukeepplin.bsky.social · 7d
Good piece on the breakthrough of mRNA vaccines for melanoma, which my wife was heavily involved in, and the other types of cancer that researchers like her are trying to tackle next. It's an exciting time in that field. www.washingtonpost.com/health/2026/...
September 19, 2026 at 11:02 PM